null Option on Structure Therapeutics
| GPCR Stock | 19.53 0.07 0.36% |
Structure Therapeutics' latest option contracts expiring on October 17th 2025 are carrying combined implied volatility of 1.01 with a put-to-call open interest ratio of 0.54 over 23 outstanding agreements suggesting investors are buying more calls than puts on contracts expiring on October 17th 2025.
Open Interest Against October 17th 2025 Option Contracts
2025-10-17
The chart above shows Structure Therapeutics' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Structure Therapeutics' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Structure Therapeutics' option, there is no secondary market available for investors to trade.
Structure Therapeutics Maximum Pain Price Across 2025-10-17 Option Contracts
Max pain occurs when Structure Therapeutics' market makers reach a net positive position across all Structure Therapeutics' options at a strike price where option holders stand to lose the most money. By contrast, Structure Therapeutics' option sellers may reap the most after selling more options than buying, causing them to expire worthless.
In The Money vs. Out of Money Option Contracts on Structure Therapeutics
Analyzing Structure Therapeutics' in-the-money options over time can help investors to take a profitable long position in Structure Therapeutics regardless of its overall volatility. This is especially true when Structure Therapeutics' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Structure Therapeutics' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Structure Therapeutics' stock while costing only a fraction of its price.
Structure Therapeutics In The Money Call Balance
When Structure Therapeutics' strike price is surpassing the current stock price, the option contract against Structure Therapeutics American stock is said to be in the money. When it comes to buying Structure Therapeutics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Structure Therapeutics American are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Structure Current Options Market Mood
Structure Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Structure Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Most options investors, including buyers and sellers of Structure Therapeutics' calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. Structure Therapeutics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Structure contract
Base on the Rule 16, the options market is currently suggesting that Structure Therapeutics American will have an average daily up or down price movement of about 0.0631% per day over the life of the 2025-10-17 option contract. With Structure Therapeutics trading at USD 19.53, that is roughly USD 0.0123. If you think that the market is fully incorporating Structure Therapeutics' daily price movement you should consider buying Structure Therapeutics American options at the current volatility level of 1.01%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Structure | Build AI portfolio with Structure Stock |
Purchasing Structure Therapeutics options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Structure calls. Remember, the seller must deliver Structure Therapeutics American stock to the call owner when a call is exercised.
Structure Therapeutics Option Chain
When Structure Therapeutics' strike price is surpassing the current stock price, the option contract against Structure Therapeutics American stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Structure Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on Structure. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Structure. It also shows strike prices and maturity days for a Structure Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | GPCR251017C00037500 | 2 | 37.5 | 0.0 - 2.8 | 1.65 | Out |
Call | GPCR251017C00035000 | 44 | 35.0 | 0.0 - 3.0 | 0.95 | Out |
Call | GPCR251017C00032500 | 114 | 32.5 | 0.0 - 1.55 | 0.7 | Out |
Call | GPCR251017C00030000 | 171 | 30.0 | 0.4 - 1.55 | 0.85 | Out |
Call | GPCR251017C00027500 | 44 | 27.5 | 0.05 - 2.35 | 1.96 | Out |
Call | GPCR251017C00025000 | 107 | 25.0 | 0.55 - 2.0 | 1.65 | Out |
Call | GPCR251017C00022500 | 104 | 22.5 | 1.45 - 3.2 | 2.25 | Out |
Call | GPCR251017C00020000 | 441 | 20.0 | 2.25 - 4.2 | 3.1 | Out |
Call | GPCR251017C00017500 | 21 | 17.5 | 2.55 - 6.0 | 7.2 | In |
Call | GPCR251017C00015000 | 5 | 15.0 | 4.3 - 7.5 | 8.4 | In |
Call | GPCR251017C00010000 | 1 | 10.0 | 8.2 - 11.6 | 9.44 | In |
Put | GPCR251017P00037500 | 0 | 37.5 | 17.2 - 20.5 | 17.2 | In |
Put | GPCR251017P00035000 | 0 | 35.0 | 14.9 - 17.9 | 14.9 | In |
Put | GPCR251017P00032500 | 0 | 32.5 | 12.5 - 15.5 | 12.5 | In |
Put | GPCR251017P00030000 | 2 | 30.0 | 10.4 - 13.5 | 10.4 | In |
Put | GPCR251017P00027500 | 191 | 27.5 | 8.1 - 10.6 | 8.9 | In |
Put | GPCR251017P00025000 | 9 | 25.0 | 6.1 - 8.9 | 6.1 | In |
Put | GPCR251017P00022500 | 9 | 22.5 | 4.1 - 6.7 | 3.75 | In |
Put | GPCR251017P00020000 | 159 | 20.0 | 2.85 - 4.8 | 4.2 | In |
Put | GPCR251017P00017500 | 11 | 17.5 | 1.05 - 3.9 | 2.64 | Out |
Put | GPCR251017P00015000 | 181 | 15.0 | 0.4 - 2.8 | 1.3 | Out |
Put | GPCR251017P00012500 | 6 | 12.5 | 0.0 - 3.0 | 3.0 | Out |
Put | GPCR251017P00010000 | 2 | 10.0 | 0.0 - 3.0 | 3.0 | Out |
Structure Total Stockholder Equity
Total Stockholder Equity |
|
Structure Therapeutics Corporate Management
| Lani Ibarra | Senior Operations | Profile | |
| Hui Lei | Senior Chemistry | Profile | |
| Xichen Lin | Chief Officer | Profile | |
| Yingli Ma | Chief Officer | Profile | |
| Fang Zhang | Executive Biology | Profile |
Additional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.